Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study

Author(s): Emanuele D’Amico*, Aurora Zanghì, Roberta Fantozzi, Diego Centonze and Carlo Avolio

Volume 21, Issue 12, 2023

Published on: 03 August, 2023

Page: [2563 - 2566] Pages: 4

DOI: 10.2174/1570159X21666230803161825

Price: $65

Abstract

Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen.

Methods: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naïve to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naïve patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting.

Results: Fifteen patients were enrolled. CD3+ T cell frequencies were higher at time 1 (%80.4, SD 7.7) and time 2 (%82.6, SD 5.8) when compared to time 0 (%72.4, SD 9.8), p = .013. B naïve cells were barely detectable in the OFA group at time 1 (%0.4, SD 0.5) and 2 (%1.4, SD 2.9) when compared to time 0 (%11.5, SD 3.8), p < .001.

Conclusion: The progressive and increasing use of anti-CD20 drugs imposes the need for larger, prospective, real-world, long-term studies to characterize further immunophenotypes of patients with RMS treated with OFA.

« Previous Next »
Graphical Abstract

[1]
Available from:https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdfAccessed on September 2022.
[2]
Kang, C.; Blair, H.A. Ofatumumab: A review in relapsing forms of multiple sclerosis. Drugs, 2022, 82(1), 55-62.
[http://dx.doi.org/10.1007/s40265-021-01650-7] [PMID: 34897575]
[3]
Hauser, S.L.; Bar-Or, A.; Cohen, J.A.; Comi, G.; Correale, J.; Coyle, P.K.; Cross, A.H.; de Seze, J.; Leppert, D.; Montalban, X.; Selmaj, K.; Wiendl, H.; Kerloeguen, C.; Willi, R.; Li, B.; Kakarieka, A.; Tomic, D.; Goodyear, A.; Pingili, R.; Häring, D.A.; Ramanathan, K.; Merschhemke, M.; Kappos, L. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med., 2020, 383(6), 546-557.
[http://dx.doi.org/10.1056/NEJMoa1917246] [PMID: 32757523]
[4]
D’Amico, E.; Zanghì, A.; Gastaldi, M.; Patti, F.; Zappia, M.; Franciotta, D. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun. Rev., 2019, 18(7), 665-672.
[http://dx.doi.org/10.1016/j.autrev.2019.05.003] [PMID: 31059839]
[5]
Sanford, M.; McCormack, P.L. Ofatumumab. Drugs, 2010, 70(8), 1013-1019.
[http://dx.doi.org/10.2165/11203850-000000000-00000] [PMID: 20481657]
[6]
Thompson, A.J.; Baranzini, S.E.; Geurts, J.; Hemmer, B.; Ciccarelli, O. Multiple sclerosis. Lancet, 2018, 391(10130), 1622-1636.
[http://dx.doi.org/10.1016/S0140-6736(18)30481-1] [PMID: 29576504]
[7]
Faissner, S.; Heitmann, N.; Plaza-Sirvent, C.; Trendelenburg, P.; Ceylan, U.; Motte, J.; Bessen, C.; Urlaub, D.; Watzl, C.; Overheu, O.; Reinacher-Schick, A.; Hellwig, K.; Pfaender, S.; Schmitz, I.; Gold, R. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. Front. Immunol., 2022, 13, 980526.
[http://dx.doi.org/10.3389/fimmu.2022.980526] [PMID: 36119053]
[8]
Signoriello, E.; Lus, G.; Bonavita, S.; Lanzillo, R.; Saccà, F.; Landi, D.; Frau, J.; Baroncini, D.; Zaffaroni, M.; Maniscalco, G.T.; Curti, E.; Sartori, A.; Cepparulo, S.; Marfia, G.A.; Nicoletti, C.G.; Carotenuto, A.; Nociti, V.; Caleri, F.; Sormani, M.P.; Signori, A. Switch from sequestering to anti-CD20 depleting treatment: Disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Mult. Scler., 2022, 28(1), 93-101.
[http://dx.doi.org/10.1177/13524585211005657] [PMID: 33855897]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy